While GH-releasing peptides don't directly alter sex hormone production, increased IGF-1 can influence SHBG and free hormone levels. Monitoring is advisable during extended protocols, especially for users with existing hormone therapy. Studies from
Endocrine Journal show growth hormone can affect sex hormone binding globulin and peripheral conversion, though effects are typically modest at standard peptide doses.